David Michael Glass

US Patent:

7632503, Dec 15, 2009

Filed:

Feb 14, 2008

Appl. No.:

12/070213

Inventors:

Trevor Stitt - Ridgewood NJ, US
Esther Latres - New York NY, US
David J. Glass - Cortlandt Manor NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
A61K 38/00

US Classification:

4241581, 514 12

Abstract:

A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.

US Patent:

7842096, Nov 30, 2010

Filed:

Feb 22, 2005

Appl. No.:

11/063030

Inventors:

Natalia Fridshtand - Ringwood NJ, US
Douglas W. Gabel - Pompton Plains NJ, US
Steven J. Charlebois - Goshen IN, US
David L. Glass - Silver Lake IN, US
Steven Zawadzki - Lessburg IN, US
Jeffrey P. Matney - Pierceton IN, US

Assignee:

Zimmer Technology, Inc. - Warsaw IN

International Classification:

A61F 2/36

US Classification:

623 2335, 623 2211, 623 2315, 623 233

Abstract:

A hip prosthesis for insertion into a femur. In one exemplary embodiment, the hip prosthesis includes a stem having a proximal end, a distal end, and a longitudinal axis. This stem may include anterior and posterior locking surfaces which diverge away from the stem. A shank portion may extend distally from the anterior and posterior locking surfaces and converge at an angle distally toward the stem.

US Patent:

8420088, Apr 16, 2013

Filed:

Jan 29, 2010

Appl. No.:

12/696693

Inventors:

David Glass - East Hanover NJ, US
Shou-Ih Hu - East Hanover NJ, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 38/18
A61K 39/395
C07K 14/50
C07K 16/00
C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63

US Classification:

4241341, 4353201, 435243, 435325, 435 697, 514 91, 514 212

Abstract:

The present invention is directed to fusion polypeptides comprising Klotho protein or an active fragment thereof and FGF23 or an active fragment thereof.

US Patent:

8206455, Jun 26, 2012

Filed:

Sep 13, 2010

Appl. No.:

12/880365

Inventors:

Natalia Fridshtand - Ringwood NJ, US
Douglas W. Gabel - Pompton Plains NJ, US
Steven J. Charlebois - West Lafayette IN, US
David L. Glass - Silver Lake IN, US
Steven A. Zawadzki - Leesburg IN, US
Jeffrey P. Matney - Pierceton IN, US

Assignee:

Zimmer Technology, Inc. - Warsaw IN

International Classification:

A61F 2/36

US Classification:

623 2335, 623 2211, 623 2311, 623 235

Abstract:

A hip prosthesis is provided for insertion into a femur. In one exemplary embodiment, the hip prosthesis includes a stem having a proximal end, a distal end, and a longitudinal axis. This stem may include anterior and posterior locking surfaces which diverge away from the longitudinal axis. A shank portion may extend distally from the anterior and posterior locking surfaces and converge at an angle distally toward the longitudinal axis.

US Patent:

20120221116, Aug 30, 2012

Filed:

May 7, 2012

Appl. No.:

13/465172

Inventors:

Natalia Fridshtand - Ringwood NJ, US
Douglas W. Gabel - Pompton Plains NJ, US
Steven J. Charlebois - West Lafayette IN, US
David L. Glass - Silver Lake IN, US
Steven Zawadzki - Leesburg IN, US
Jeffrey P. Matney - Pierceton IN, US

Assignee:

ZIMMER, INC. - Warsaw IN

International Classification:

A61F 2/36

US Classification:

623 233

Abstract:

A hip prosthesis is provided for insertion into a femur. In one exemplary embodiment, the hip prosthesis includes a stem having a proximal end, a distal end, and a longitudinal axis. This stem may include anterior and posterior locking surfaces which diverge away from the longitudinal axis. A shank portion may extend distally from the anterior and posterior locking surfaces and converge at an angle distally toward the longitudinal axis.

US Patent:

56228627, Apr 22, 1997

Filed:

Nov 14, 1994

Appl. No.:

8/339578

Inventors:

Stephen P. Squinto - Irvington NY
David Glass - New York NY
Thomas H. Aldrich - New York NY
Peter DiStefano - Carmel NY
Trevor Stitt - Huntington Station NY
Mark E. Furth - Pelham NY
George D. Yancopoulos - Briarcliff Manor NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 1500
C12N 510

US Classification:

435353

Abstract:

The present invention provides for assay systems that may be used to detect and/or measure neurotrophin activity or to identify agents that exhibit neurotrophin-like activity, and for methods of using such assay systems. It is based, at least in part, on the discovery that the trkB protooncogene encodes a tyrosine kinase receptor that may serve as a functional binding protein for BDNF and NT-3. Such assay systems may be of particular value in identifying new neurotrophins or agents with neurotrophin-like activity. In various embodiments, the assay systems and methods of the invention may be used to detect and/or measure the binding of neurotrophin to trkB, either using direct binding studies or the detection of the secondary affects of trkB/neurotrophin binding. The present invention also has diagnostic and therapeutic utilities. In particular embodiments of the invention, methods of detecting aberrancies in trkB function or expression may be used in the diagnosis of neurological disorders.

US Patent:

58144781, Sep 29, 1998

Filed:

May 10, 1996

Appl. No.:

8/644271

Inventors:

David M. Valenzuela - Franklin Square NY
David J. Glass - White Plains NY
David C. Bowen - Yonkers NY
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12P 2106

US Classification:

435 651

Abstract:

The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated and purified polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.

US Patent:

6143714, Nov 7, 2000

Filed:

Mar 18, 1997

Appl. No.:

8/820684

Inventors:

Vivien Wong - Scarsdale NY
Gregory Conn - Bedford Hills NY
David Glass - White Plains NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 3816
C07K 14435
C07K 14475

US Classification:

514 2

Abstract:

The present invention provides for a method of promoting motor neuron survival, growth or differentiation comprising treating motor neurons with an effective amount of HGF. The invention also provides for a method of promoting motor neuron survival, growth or differentiation comprising treating motor neurons with an effective amount of HGF and an effective amount of CNTF. The invention further provides for a method of alleviating the toxic effects of vincristine on motor neurons comprising treating motor neurons with an effective amount of HGF and an effective amount of CNTF. The methods may be carried out in vitro or in vivo. The invention also provides a method of treating a motor neuron disorder in a patient comprising administering to the patient an effective amount of HGF and CNTF. The invention further provides a pharmaceutical composition for treating a motor neuron disorder in a patient comprising HGF and CNTF in a pharmacologically acceptable carrier.